secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vor Biopharma Inc. (VOR)
CIK:        0001817229
Form:       8-K
Filed at:   2025-11-03T23:59:59+00:00
Accession:  0001193125-25-261723
Event type: leadership
Sentiment:  positive
Materiality: 0.70
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vor Bio appoints Jeremy Sokolove CMO; amends CDO severance terms
----------------------------------------------------------------

- Dr. Jeremy Sokolove appointed CMO effective Nov 3, 2025; has >20 yrs rheumatology/autoimmune R&D experience.
- Sokolove previously CMO-in-Residence at Roivant Sciences, SVP at GSK, Head of Immunology at AbbVie.
- Vor Bio emphasizes Telitacicept (dual BAFF/APRIL inhibitor) as near-term opportunity for autoimmune patients.
- Amended CDO Dr. Qing Zuraw's severance: pro-rated 2025/2026 target bonus if terminated w/o cause, or if resigns after Dec 31, 2025.
- Employment amendment effective for five months from Nov 2, 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1817229/000119312525261723/0001193125-25-261723-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1817229/000119312525261723/vor-20251102.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-261723

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer